At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients.
Evaluating genomic tests for breast cancer management
13th January 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?